Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality.

ABSTRACT: The advanced development of synthetic lethality has opened the doors for specific anti-cancer medications of personalized medicine and efficient therapies against cancers. One of the most popular approaches being investigated is targeting DNA repair pathways as the implementation of the PARP inhibitor (PARPi) into individual or combinational therapeutic schemes. Such treatment has been effectively employed against homologous recombination-defective solid tumors as well as hematopoietic malignancies. However, the resistance to PARPi has been observed in both preclinical research and clinical treatment. Therefore, elucidating the mechanisms responsible for the resistance to PARPi is pivotal for the further success of this intervention. Apart from mechanisms of acquired resistance, the bone m

SUBMITTER: Le BV 

PROVIDER: S-EPMC9741207 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature